Wells Fargo & Company Clovis Oncology, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.85 $34,173 - $92,756	32,546 Added 68.18%	80,284 $96,000
Q2 2022 Aug 12, 2022	SELL	$0.63 - $2.96 $36,633 - $172,118	-58,148 Reduced 54.92%	47,738 $86,000
Q1 2022 May 16, 2022	SELL	$1.43 - $3.14 $75,259 - $165,255	-52,629 Reduced 33.2%	105,886 $214,000
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.76 $79,722 - $140,548	-29,527 Reduced 15.7%	158,515 $430,000
Q3 2021 Nov 15, 2021	BUY	$4.06 - $5.8 $44,241 - $63,202	10,897 Added 6.15%	188,042 $839,000
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $323,147 - $453,822	64,372 Added 57.08%	177,145 $1.03 Million
Q1 2021 May 13, 2021	SELL	$4.81 - $10.34 $643,351 - $1.38 Million	-133,753 Reduced 54.26%	112,773 $791,000
Q4 2020 Feb 09, 2021	BUY	$4.13 - $6.41 $158,996 - $246,772	38,498 Added 18.51%	246,526 $1.18 Million
Q3 2020 Nov 05, 2020	SELL	$4.82 - $7.72 $32,192 - $51,561	-6,679 Reduced 3.11%	208,028 $1.21 Million
Q2 2020 Aug 13, 2020	BUY	$5.69 - $9.69 $794,130 - $1.35 Million	139,566 Added 185.74%	214,707 $1.45 Million
Q1 2020 May 14, 2020	BUY	$3.77 - $11.0 $283,281 - $826,551	75,141 New	75,141 $479,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.